Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program
Clinical Infectious Diseases · 07.10.2026 · 83 (3) · e526-e529
DOI: 10.1093/cid/ciag271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.04.2026. Verfasst von Stuart H Cohen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Coccidioidomycosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basilea Pharmaceutica International Ltd.
Abstract (Originalsprache)
Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix (“gepix”), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; nonmeningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, California, USA.
- Department of Internal Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
- University of California SanFrancisco, San Francisco, California, USA.
- Division of Infectious Diseases, George Washington University School of Medicine and Health Sciences, Washington D. C., USA.
- Department of Internal Medicine, Division of Infectious Diseases, City of Hope, Duarte, California, USA.
- Department of Internal Medicine, Division of Infectious Diseases, Kaiser Permanente Northwest, Portland, Oregon, USA.
ORCID-Profile: Stuart H Cohen, Paul Allyn, Jennifer Rathe, Gerald Hutfles, Tara Vijayan, Ethan A Smith, Dan Ilges, George R Thompson
Förderung
- Basilea Pharmaceutica International Ltd
Zitieren
APA
Cohen, S. H., Allyn, P., Chow, F. C., Rathe, J., Nanayakkara, D. D., Hutfles, G., Vijayan, T., Smith, E. A., Saling, C. F., Ilges, D., Schlamm, H. T., & Thompson, G. R. (2026). Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program. Clinical Infectious Diseases, 83(3), e526-e529. https://doi.org/10.1093/cid/ciag271
Vancouver
Cohen SH, Allyn P, Chow FC, Rathe J, Nanayakkara DD, Hutfles G, et al. Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program. Clinical Infectious Diseases. 2026;83(3):e526-e529. doi:10.1093/cid/ciag271
BibTeX
@article{Cohen2026,
author = {Cohen, Stuart H and Allyn, Paul and Chow, Felicia C and Rathe, Jennifer and Nanayakkara, Deepa D and Hutfles, Gerald and Vijayan, Tara and Smith, Ethan A and Saling, Christopher F and Ilges, Dan and Schlamm, Haran T and Thompson, George R},
title = {Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {3},
pages = {e526--e529},
doi = {10.1093/cid/ciag271}
}
EUVIMED